Intera Atlas
Run match
Sites / Houston Research Institute
Is this you?

Request access for Houston Research Institute with your @houstonresearchinstitute.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.

Request account

Houston Research Institute

Unclaimed profile

Site Network (specialty) · Houston, TX · ~1 (specialty site, now part of Summit network) sites

WebsiteRank for protocol
Intera lens
ICP 5Lift (cardio sample) 0.23Recruit soph 0.43
Quality Scorecard (1–100)
Overall70Recruit51Ops77Sponsor81Ther76

Performance (observed)

Historical trials
232
Completed
124
Terminated/Withdrawn
26
Completion rate
83%
Active now
75
Phase 2
60
Phase 3
124
Realized enrollment
165,503
First study year
1997
Years active
29
Match confidence
high
Enrollment velocity (inf)
5,707

Therapeutic

Areas
Hepatology, Gastroenterology, MASH, MASLD, cirrhosis, obesity, NAFLD, NASH, hepatitis B/C, primary biliary cholangitis, primary sclerosis cholangitis
Specialties
Hepatology/Gastroenterology: NAFLD, NASH, obesity, Hepatitis B/C, PBC, PSC, cirrhosis, GI diseases
Breadth (conditions)
342
States
TX

Recruitment (web observed)

Patient database
Y - Volunteer database maintained
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y - Fatty liver focus content, FAQ pages
Capability notes
Volunteer database, referring physician referrals, MASH/MASLD specialty focus

Relationships

Sponsors
Eli Lilly and Company; Pfizer; AbbVie; Janssen Research & Development, LLC; Boehringer Ingelheim; SWOG Cancer Research Network
CROs
Clinipace Worldwide; ICON Clinical Research; MacroGenics; Medpace, Inc.; MicroTransponder Inc.; Microbion Corporation
Owner / parent
Acquired by Summit Clinical Research & Pinnacle (May 2025); founded 2022 by Dr. Mazen Noureddin and late Dr. Stephen Harrison

Capacity & people

Investigators
—
Coordinators
—
CEO
Unknown (Dr. Mazen Noureddin Co-Chairman as of 2025)
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown

Tech & DCT

Builds tech
Unknown
Home visits
N
DCT / decentralized
N - Houston-based
Tech stack
Not mentioned
Recruiting visible
Y

Notes

Founded 2022 (recent, growth signal). Acquired by Summit/Pinnacle May 2025 (roll-up consolidation signal). MASH/MASLD/cirrhosis specialty site. Part of larger Summit network (120+ sites). Single specialty site. Moderate fit: Recent founding, acquired into larger network, metabolic disease focus (good for Intera), but limited standalone capability. [Validated: 9 active recruiting cardiometabolic trials on ClinicalTrials.gov.]

Recommendation features (sample indication)

Ind fit 0.40Liftability 0.23Overall70

FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.